LaNova Medicines, the Shanghai-based biotechnology firm focused on novel biologic drugs for cancer treatment, has secured $200.0M in new capital. The clinical-stage company, founded in 2019, is committed to discovering and developing innovative treatments, aiming to address the unmet clinical needs of cancer patients.
Leveraging proprietary technology platforms and a deep understanding of the tumor microenvironment, LaNova Medicines has built a differentiated pipeline of products. The company, led by industry veterans, operates as an R&D engine, striving to progress its programs toward the clinic.
